Develops drugs for rare diseases.
Dec 2024Revenue $26.0K/yrExpenses $1.35M/yr
No trendCash runway ≈ 3 months from Jun 2026
Figures by year
When will Viskase Holdings be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2024, revenue was $26.0K and expenses $1.35M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2024 | $26.0K | $1.35M | −$1.33M |
| Dec 2022 | $26.0K | $1.06M | −$1.03M |
| Dec 2021 | $701K | $1.17M | −$469K |
| Dec 2020 | $52.0K | $1.36M | −$1.30M |
| Dec 2019 | $207K | $1.18M | −$973K |
| Dec 2015 | $17.5M | $6.66M | $10.8M |
| Dec 2014 | $31.2M | $2.38M | $28.8M |
| Dec 2013 | $34.5M | $16.3M | $18.2M |
| Dec 2012 | $42.6M | $46.6M | −$3.97M |
| Dec 2011 | $48.1M | $64.5M | −$16.5M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.